Seizure-Induced Up-Regulation of P-Glycoprotein at the Blood-Brain Barrier through Glutamate and Cyclooxygenase-2 Signaling

Increased expression of drug efflux transporters at the blood-brain barrier accompanies epileptic seizures and complicates therapy with antiepileptic drugs. This study is concerned with identifying mechanistic links that connect seizure activity to increased P-glycoprotein expression at the blood-br...

Full description

Saved in:
Bibliographic Details
Published inMolecular pharmacology Vol. 73; no. 5; pp. 1444 - 1453
Main Authors Bauer, Björn, Hartz, Anika M S, Pekcec, Anton, Toellner, Kathrin, Miller, David S, Potschka, Heidrun
Format Journal Article
LanguageEnglish
Published United States American Society for Pharmacology and Experimental Therapeutics 01.05.2008
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Increased expression of drug efflux transporters at the blood-brain barrier accompanies epileptic seizures and complicates therapy with antiepileptic drugs. This study is concerned with identifying mechanistic links that connect seizure activity to increased P-glycoprotein expression at the blood-brain barrier. In this regard, we tested the hypothesis that seizures increase brain extracellular glutamate, which signals through an N -methyl- d -aspartate (NMDA) receptor and cyclooxygenase-2 (COX-2) in brain capillaries to increase blood-brain barrier P-glycoprotein expression. Consistent with this hypothesis, exposing isolated rat or mouse brain capillaries to glutamate for 15 to 30 min increased P-glycoprotein expression and transport activity hours later. These increases were blocked by 5 H -dibenzo[ a , d ]cyclohepten-5,10-imine (dizocilpine maleate) (MK-801), an NMDA receptor antagonist, and by celecoxib, a selective COX-2 inhibitor; no such glutamate-induced increases were seen in brain capillaries from COX-2-null mice. In rats, intracerebral microinjection of glutamate caused locally increased P-glycoprotein expression in brain capillaries. Moreover, using a pilocarpine status epilepticus rat model, we observed seizure-induced increases in capillary P-glycoprotein expression that were attenuated by administration of indomethacin, a COX inhibitor. Our findings suggest that brain uptake of some antiepileptic drugs can be enhanced through COX-2 inhibition. Moreover, they provide insight into one mechanism that underlies drug resistance in epilepsy and possibly other central nervous system disorders.
AbstractList Increased expression of drug efflux transporters at the blood-brain barrier accompanies epileptic seizures and complicates therapy with antiepileptic drugs. This study is concerned with identifying mechanistic links that connect seizure activity to increased P-glycoprotein expression at the blood-brain barrier. In this regard, we tested the hypothesis that seizures increase brain extracellular glutamate, which signals through an N-methyl-d-aspartate (NMDA) receptor and cyclooxygenase-2 (COX-2) in brain capillaries to increase blood-brain barrier P-glycoprotein expression. Consistent with this hypothesis, exposing isolated rat or mouse brain capillaries to glutamate for 15 to 30 min increased P-glycoprotein expression and transport activity hours later. These increases were blocked by 5H-dibenzo[a,d]cyclohepten-5,10-imine (dizocilpine maleate) (MK-801), an NMDA receptor antagonist, and by celecoxib, a selective COX-2 inhibitor; no such glutamate-induced increases were seen in brain capillaries from COX-2-null mice. In rats, intracerebral microinjection of glutamate caused locally increased P-glycoprotein expression in brain capillaries. Moreover, using a pilocarpine status epilepticus rat model, we observed seizure-induced increases in capillary P-glycoprotein expression that were attenuated by administration of indomethacin, a COX inhibitor. Our findings suggest that brain uptake of some antiepileptic drugs can be enhanced through COX-2 inhibition. Moreover, they provide insight into one mechanism that underlies drug resistance in epilepsy and possibly other central nervous system disorders.
Increased expression of drug efflux transporters at the blood-brain barrier accompanies epileptic seizures and complicates therapy with antiepileptic drugs. This study is concerned with identifying mechanistic links that connect seizure activity to increased P-glycoprotein expression at the blood-brain barrier. In this regard, we tested the hypothesis that seizures increase brain extracellular glutamate, which signals through an N -methyl- d -aspartate (NMDA) receptor and cyclooxygenase-2 (COX-2) in brain capillaries to increase blood-brain barrier P-glycoprotein expression. Consistent with this hypothesis, exposing isolated rat or mouse brain capillaries to glutamate for 15 to 30 min increased P-glycoprotein expression and transport activity hours later. These increases were blocked by 5 H -dibenzo[ a , d ]cyclohepten-5,10-imine (dizocilpine maleate) (MK-801), an NMDA receptor antagonist, and by celecoxib, a selective COX-2 inhibitor; no such glutamate-induced increases were seen in brain capillaries from COX-2-null mice. In rats, intracerebral microinjection of glutamate caused locally increased P-glycoprotein expression in brain capillaries. Moreover, using a pilocarpine status epilepticus rat model, we observed seizure-induced increases in capillary P-glycoprotein expression that were attenuated by administration of indomethacin, a COX inhibitor. Our findings suggest that brain uptake of some antiepileptic drugs can be enhanced through COX-2 inhibition. Moreover, they provide insight into one mechanism that underlies drug resistance in epilepsy and possibly other central nervous system disorders.
Author Heidrun Potschka
Anton Pekcec
David S. Miller
Kathrin Toellner
Björn Bauer
Anika M. S. Hartz
Author_xml – sequence: 1
  givenname: Björn
  surname: Bauer
  fullname: Bauer, Björn
  organization: Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-University Munich, Koeniginstr. 16, 80539 Munich, Germany
– sequence: 2
  givenname: Anika M S
  surname: Hartz
  fullname: Hartz, Anika M S
– sequence: 3
  givenname: Anton
  surname: Pekcec
  fullname: Pekcec, Anton
– sequence: 4
  givenname: Kathrin
  surname: Toellner
  fullname: Toellner, Kathrin
– sequence: 5
  givenname: David S
  surname: Miller
  fullname: Miller, David S
– sequence: 6
  givenname: Heidrun
  surname: Potschka
  fullname: Potschka, Heidrun
BackLink https://www.ncbi.nlm.nih.gov/pubmed/18094072$$D View this record in MEDLINE/PubMed
BookMark eNpFkEFv1DAQhS1URLeFK0fkEzcvtuMkzpFdwVKpEohSiZs160wSI8denEQQ-PMY7Uo9zWj03puZ74ZchRiQkNeCb4WQ6t0Y_VbwesuVkII_IxtRSsG4EOKKbDiXFdNN-f2a3EzTD86FKjV_Qa6F5o3itdyQvw_o_iwJ2V1oF4stfTyxr9gvHmYXA40d_cIOfrXxlOKMLlCY6Twg3fkYW7ZLkEc7SMlhyvMUl36gB7_MMMKMFEJL96vN2t9rjwEmZJI-uD6Ad6F_SZ534Cd8dam35PHjh2_7T-z-8-Fu__6eWSXFzJp8qrUCeAEN11WNtquOTS3LstUIWtRlo6EFa9URS6x0p7CwpdR1JbMVbHFL3p5z8w8_F5xmM7rJovcQMC6TkbxqMpEiC7dnoU1xmhJ25pTcCGk1gpv_uE3GnfvanHFnw5tL8nIcsX2SX_g-rR5cP_xyCc1pgDSCjT72q6kLUxqhlCr-AWZAi68
CitedBy_id crossref_primary_10_1016_j_phrs_2015_02_001
crossref_primary_10_1016_j_biomaterials_2015_09_041
crossref_primary_10_3389_fnagi_2024_1368200
crossref_primary_10_1517_17425255_2016_1168804
crossref_primary_10_1371_journal_pone_0140918
crossref_primary_10_1016_j_biomaterials_2015_10_050
crossref_primary_10_3390_life13061294
crossref_primary_10_3389_fnins_2019_01358
crossref_primary_10_1111_ejn_15079
crossref_primary_10_1111_j_1528_1167_2010_02585_x
crossref_primary_10_1007_s11095_022_03427_3
crossref_primary_10_1038_clpt_2009_138
crossref_primary_10_1038_scibx_2008_991
crossref_primary_10_1002_epi4_12590
crossref_primary_10_1155_2015_194541
crossref_primary_10_5059_yukigoseikyokaishi_73_254
crossref_primary_10_3389_fnins_2022_851394
crossref_primary_10_1016_j_nbd_2019_02_010
crossref_primary_10_1016_j_yebeh_2019_02_012
crossref_primary_10_1002_ana_23567
crossref_primary_10_1007_s11064_022_03803_w
crossref_primary_10_1038_nrn2995
crossref_primary_10_1586_14737175_2016_1158101
crossref_primary_10_1111_epi_12461
crossref_primary_10_1016_j_brainres_2021_147303
crossref_primary_10_1016_j_bbcan_2023_188957
crossref_primary_10_1089_neu_2012_2587
crossref_primary_10_1016_j_neuropharm_2019_107742
crossref_primary_10_1016_j_addr_2011_11_008
crossref_primary_10_1016_j_ejphar_2022_175327
crossref_primary_10_1111_epi_17751
crossref_primary_10_1016_j_cotox_2018_12_004
crossref_primary_10_1038_s41467_023_36070_6
crossref_primary_10_1016_j_xcrm_2024_101609
crossref_primary_10_3390_cancers14174285
crossref_primary_10_1016_j_yebeh_2020_107659
crossref_primary_10_1016_j_eplepsyres_2008_10_010
crossref_primary_10_1016_j_hsr_2023_100141
crossref_primary_10_1016_j_eplepsyres_2014_02_012
crossref_primary_10_1124_mol_108_046680
crossref_primary_10_1208_s12248_017_0096_2
crossref_primary_10_2217_pgs_10_126
crossref_primary_10_1016_j_brainres_2011_04_003
crossref_primary_10_1016_j_phrs_2019_04_031
crossref_primary_10_1007_s11095_008_9735_8
crossref_primary_10_1111_j_1528_1167_2010_02671_x
crossref_primary_10_1007_s12035_024_04274_6
crossref_primary_10_3109_00207454_2014_989321
crossref_primary_10_1111_j_1528_1167_2011_03034_x
crossref_primary_10_1016_j_neuroscience_2014_10_021
crossref_primary_10_3389_fvets_2022_864293
crossref_primary_10_1177_0271678X15608644
crossref_primary_10_14581_jer_21003
crossref_primary_10_3390_molecules22030365
crossref_primary_10_1002_med_21573
crossref_primary_10_1124_pr_120_019539
crossref_primary_10_1038_jcbfm_2010_21
crossref_primary_10_1016_j_eplepsyres_2016_11_004
crossref_primary_10_1007_s00210_023_02485_7
crossref_primary_10_1016_j_yebeh_2024_109890
crossref_primary_10_1007_s11064_014_1499_4
crossref_primary_10_1073_pnas_1203534109
crossref_primary_10_1016_j_eplepsyres_2017_02_003
crossref_primary_10_1210_en_2012_1316
crossref_primary_10_1371_journal_pone_0125389
crossref_primary_10_1016_j_neuropharm_2014_05_002
crossref_primary_10_1186_s12974_019_1592_3
crossref_primary_10_1021_mp2001022
crossref_primary_10_3390_ijms232314667
crossref_primary_10_1111_j_1528_1167_2008_01916_x
crossref_primary_10_1002_glia_22312
crossref_primary_10_1111_epi_14586
crossref_primary_10_1016_j_neurobiolaging_2009_08_014
crossref_primary_10_1021_mp4001102
crossref_primary_10_1016_j_neulet_2018_10_016
crossref_primary_10_1111_bcpt_12973
crossref_primary_10_1517_14740338_2015_1010508
crossref_primary_10_3233_JAD_201074
crossref_primary_10_36485_1561_6274_2021_25_1_83_89
crossref_primary_10_1002_sstr_202300508
crossref_primary_10_1096_fj_201901369RR
crossref_primary_10_3390_cells13090740
crossref_primary_10_1111_epi_14505
crossref_primary_10_3390_membranes13060568
crossref_primary_10_1007_s10309_010_0105_2
crossref_primary_10_1248_bpb_34_360
crossref_primary_10_14814_phy2_15239
crossref_primary_10_1155_2013_648268
crossref_primary_10_2133_dmpk_DMPK_14_RG_004
crossref_primary_10_1111_epi_17063
crossref_primary_10_1016_j_brainres_2014_08_060
crossref_primary_10_1021_jm301084z
crossref_primary_10_1080_14756366_2021_1956912
crossref_primary_10_1002_smll_202300395
crossref_primary_10_1007_s10695_020_00911_8
crossref_primary_10_1016_j_eplepsyres_2010_06_011
crossref_primary_10_1016_j_neuropharm_2009_09_012
crossref_primary_10_1124_jpet_114_218180
crossref_primary_10_2174_1389450120666190308144448
crossref_primary_10_1007_s12031_022_02056_0
crossref_primary_10_1002_cpt_64
crossref_primary_10_1016_j_nbd_2023_106249
crossref_primary_10_1080_14728222_2022_2039120
crossref_primary_10_1177_0271678X17705786
crossref_primary_10_3390_pharmaceutics12100966
crossref_primary_10_1016_j_yebeh_2019_07_031
crossref_primary_10_1007_s12035_024_03969_0
crossref_primary_10_1124_mol_116_107169
crossref_primary_10_1016_j_tvjl_2023_106014
crossref_primary_10_1016_j_expneurol_2019_04_002
crossref_primary_10_1016_j_drudis_2016_09_017
crossref_primary_10_1017_S1461145710001161
crossref_primary_10_1016_j_tvjl_2023_105956
crossref_primary_10_1016_j_neuropharm_2011_05_027
crossref_primary_10_1093_neuonc_nos199
crossref_primary_10_21508_1027_4065_2021_66_2_6_12
crossref_primary_10_1016_j_neurobiolaging_2015_05_020
crossref_primary_10_1021_mp500841w
crossref_primary_10_1002_jps_24697
crossref_primary_10_2174_1871527319999200819093109
crossref_primary_10_1523_JNEUROSCI_2751_17_2018
crossref_primary_10_1016_j_pharmthera_2013_01_009
crossref_primary_10_1097_CCO_0b013e32833de99d
crossref_primary_10_1016_j_neuroimage_2016_05_045
crossref_primary_10_1016_j_foodres_2017_10_010
crossref_primary_10_1016_j_heliyon_2020_e04557
crossref_primary_10_1016_j_yebeh_2019_106451
crossref_primary_10_1021_acs_molpharmaceut_6b00770
crossref_primary_10_1016_j_neuroimage_2011_11_029
crossref_primary_10_1515_revneuro_2017_0043
crossref_primary_10_1016_j_addr_2011_12_007
crossref_primary_10_1016_j_brainres_2019_146516
crossref_primary_10_1124_pharmrev_120_000025
crossref_primary_10_4155_fmc_09_137
crossref_primary_10_1248_yakushi_20_00127
crossref_primary_10_1016_j_seizure_2020_09_015
crossref_primary_10_1021_acschemneuro_8b00271
crossref_primary_10_1007_s11033_020_06033_x
crossref_primary_10_1016_j_pharmthera_2009_10_004
crossref_primary_10_1038_s41598_020_59259_x
crossref_primary_10_1016_j_neuropharm_2009_01_009
crossref_primary_10_1016_j_phrs_2008_10_002
crossref_primary_10_1016_j_plefa_2020_102056
crossref_primary_10_1248_bpb_b18_00937
crossref_primary_10_1016_j_nbd_2014_04_001
crossref_primary_10_1155_2011_670613
crossref_primary_10_1002_epi4_12537
crossref_primary_10_1517_17425255_4_10_1245
crossref_primary_10_1016_j_neuro_2022_04_010
crossref_primary_10_1016_j_brainres_2015_07_005
crossref_primary_10_1038_s41401_024_01257_0
crossref_primary_10_1111_j_1476_5381_2010_00765_x
crossref_primary_10_1096_fj_201901460RR
crossref_primary_10_1007_s40265_013_0059_6
crossref_primary_10_1016_j_pneurobio_2019_101680
crossref_primary_10_3390_ijms21020591
crossref_primary_10_1007_s12031_017_0897_x
crossref_primary_10_1007_s00011_023_01700_8
crossref_primary_10_3390_pharmaceutics13122024
crossref_primary_10_4199_C00073ED1V01Y201303GBD002
crossref_primary_10_1111_vec_12605
crossref_primary_10_1111_j_1471_4159_2012_07890_x
crossref_primary_10_1186_1471_2202_10_28
crossref_primary_10_1002_epi4_12376
crossref_primary_10_1016_j_ejps_2011_05_005
crossref_primary_10_1016_j_nbd_2010_04_006
crossref_primary_10_1186_s12987_020_00220_5
crossref_primary_10_1016_j_eplepsyres_2022_106939
crossref_primary_10_1179_1743132811Y_0000000055
crossref_primary_10_4236_jbm_2023_118014
crossref_primary_10_1016_j_neuroscience_2014_07_030
crossref_primary_10_1016_j_tvjl_2022_105828
crossref_primary_10_1124_pr_107_07109
crossref_primary_10_1159_000460513
crossref_primary_10_1124_jpet_109_152520
crossref_primary_10_1002_cpt_435
crossref_primary_10_1016_j_heliyon_2022_e09777
crossref_primary_10_1016_j_eplepsyres_2016_10_012
crossref_primary_10_1016_j_neuroscience_2010_06_073
crossref_primary_10_1016_j_eplepsyres_2018_07_008
crossref_primary_10_1016_j_arr_2024_102224
crossref_primary_10_3389_fneur_2017_00301
crossref_primary_10_3109_13880209_2011_571264
crossref_primary_10_3390_pharmaceutics14071376
crossref_primary_10_1016_j_pharmthera_2020_107554
crossref_primary_10_1111_j_1528_1167_2010_02886_x
Cites_doi 10.1016/0006-8993(88)90556-2
10.1016/0920-1211(94)00081-7
10.1016/j.brainres.2005.05.038
10.1016/j.neures.2006.06.003
10.1016/j.eplepsyres.2003.12.009
10.1038/jcbfm.1992.119
10.1369/jhc.4A6451.2005
10.1016/j.nbd.2004.07.023
10.1124/jpet.106.109876
10.1016/j.ejphar.2006.06.022
10.1016/j.lfs.2004.02.027
10.1074/jbc.M206855200
10.1016/S0197-0186(02)00101-8
10.1038/nrm1229
10.1002/ana.20078
10.1038/sj.jcbfm.9600445
10.1073/pnas.98.3.1294
10.1111/j.1528-1167.2006.00496.x
10.1016/S0006-8993(99)01797-7
10.1152/ajpheart.00520.2003
10.1124/mol.104.001503
10.1124/mol.106.023796
10.1016/j.nbd.2006.06.014
10.1358/mf.2003.25.2.723681
10.1124/mol.105.017954
10.1016/j.nbd.2007.04.002
10.1089/089771502753754091
10.1124/jpet.302.3.846
10.1016/S0920-1211(01)00272-8
10.1111/j.1471-4159.2005.03150.x
10.1124/mol.106.029512
10.1586/14737175.6.3.397
10.1016/j.nbd.2006.08.015
10.2174/0929867033456800
10.1016/S0306-4522(03)00027-7
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TK
DOI 10.1124/mol.107.041210
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Neurosciences Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Neurosciences Abstracts
DatabaseTitleList MEDLINE

Neurosciences Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1521-0111
EndPage 1453
ExternalDocumentID 10_1124_mol_107_041210
18094072
73_5_1444
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Intramural
GrantInformation_xml – fundername: Intramural NIH HHS
GroupedDBID -
0R
123
2WC
34G
39C
4.4
53G
55
5RE
5VS
AALRV
AAPBV
ABFLS
ABSGY
ABZEH
ACGFS
ADACO
ADBIT
ADCOW
AENEX
AFFNX
ALMA_UNASSIGNED_HOLDINGS
CS3
DIK
DL
E3Z
EBS
EJD
F5P
FH7
GX1
H13
HH5
HZ
IH2
INIJC
KQ8
L7B
N9A
O0-
O9-
OK1
P2P
R.V
R0Z
RHF
RHI
RPT
WOQ
X
X7M
ZA5
---
-~X
.55
.GJ
0R~
18M
AAJMC
ABCQX
ABJNI
ABSQV
ACGFO
ADBBV
AERNN
AFHIN
AFOSN
AYCSE
BAWUL
BTFSW
CGR
CUY
CVF
ECM
EIF
F9R
HZ~
K-O
LSO
MVM
NPM
TR2
UQL
W8F
XOL
YBU
YHG
ZGI
ZXP
AAYXX
CITATION
7TK
ID FETCH-LOGICAL-c421t-9940cc1a03a90867ecf6b97255d8ea817598adacc4be5e68f4e3c528762994ac3
ISSN 0026-895X
IngestDate Fri Aug 16 21:44:08 EDT 2024
Fri Aug 23 00:48:33 EDT 2024
Sat Sep 28 07:52:37 EDT 2024
Tue Jan 05 21:17:31 EST 2021
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c421t-9940cc1a03a90867ecf6b97255d8ea817598adacc4be5e68f4e3c528762994ac3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
PMID 18094072
PQID 20691803
PQPubID 23462
PageCount 10
ParticipantIDs proquest_miscellaneous_20691803
crossref_primary_10_1124_mol_107_041210
pubmed_primary_18094072
highwire_pharmacology_73_5_1444
ProviderPackageCode RHF
RHI
PublicationCentury 2000
PublicationDate 2008-05-01
PublicationDateYYYYMMDD 2008-05-01
PublicationDate_xml – month: 05
  year: 2008
  text: 2008-05-01
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular pharmacology
PublicationTitleAlternate Mol Pharmacol
PublicationYear 2008
Publisher American Society for Pharmacology and Experimental Therapeutics
Publisher_xml – name: American Society for Pharmacology and Experimental Therapeutics
References 18314494 - Mol Pharmacol. 2008 May;73(5):1343-6
2019081413572856000_73.5.1444.2
2019081413572856000_73.5.1444.1
2019081413572856000_73.5.1444.6
2019081413572856000_73.5.1444.13
2019081413572856000_73.5.1444.35
2019081413572856000_73.5.1444.5
2019081413572856000_73.5.1444.12
2019081413572856000_73.5.1444.34
2019081413572856000_73.5.1444.15
2019081413572856000_73.5.1444.37
2019081413572856000_73.5.1444.3
2019081413572856000_73.5.1444.14
2019081413572856000_73.5.1444.36
2019081413572856000_73.5.1444.31
2019081413572856000_73.5.1444.9
2019081413572856000_73.5.1444.8
2019081413572856000_73.5.1444.11
2019081413572856000_73.5.1444.33
2019081413572856000_73.5.1444.7
2019081413572856000_73.5.1444.10
2019081413572856000_73.5.1444.32
(2019081413572856000_73.5.1444.24) 2001; 297
2019081413572856000_73.5.1444.17
2019081413572856000_73.5.1444.39
2019081413572856000_73.5.1444.38
2019081413572856000_73.5.1444.19
2019081413572856000_73.5.1444.18
2019081413572856000_73.5.1444.40
(2019081413572856000_73.5.1444.16) 2002; 59
(2019081413572856000_73.5.1444.30) 1995; 268
2019081413572856000_73.5.1444.23
2019081413572856000_73.5.1444.26
2019081413572856000_73.5.1444.25
2019081413572856000_73.5.1444.20
2019081413572856000_73.5.1444.22
2019081413572856000_73.5.1444.21
2019081413572856000_73.5.1444.28
2019081413572856000_73.5.1444.27
2019081413572856000_73.5.1444.29
(2019081413572856000_73.5.1444.4) 2004; 66
References_xml – ident: 2019081413572856000_73.5.1444.18
  doi: 10.1016/0006-8993(88)90556-2
– ident: 2019081413572856000_73.5.1444.26
– volume: 66
  start-page: 413
  year: 2004
  ident: 2019081413572856000_73.5.1444.4
  publication-title: Mol Pharmacol
– ident: 2019081413572856000_73.5.1444.35
  doi: 10.1016/0920-1211(94)00081-7
– ident: 2019081413572856000_73.5.1444.19
  doi: 10.1016/j.brainres.2005.05.038
– ident: 2019081413572856000_73.5.1444.34
  doi: 10.1016/j.neures.2006.06.003
– ident: 2019081413572856000_73.5.1444.38
  doi: 10.1016/j.eplepsyres.2003.12.009
– ident: 2019081413572856000_73.5.1444.29
  doi: 10.1038/jcbfm.1992.119
– ident: 2019081413572856000_73.5.1444.37
  doi: 10.1369/jhc.4A6451.2005
– ident: 2019081413572856000_73.5.1444.39
  doi: 10.1016/j.nbd.2004.07.023
– ident: 2019081413572856000_73.5.1444.15
  doi: 10.1124/jpet.106.109876
– ident: 2019081413572856000_73.5.1444.11
  doi: 10.1016/j.ejphar.2006.06.022
– volume: 297
  start-page: 1051
  year: 2001
  ident: 2019081413572856000_73.5.1444.24
  publication-title: J Pharmacol Exp Ther
– ident: 2019081413572856000_73.5.1444.40
  doi: 10.1016/j.lfs.2004.02.027
– ident: 2019081413572856000_73.5.1444.25
  doi: 10.1074/jbc.M206855200
– ident: 2019081413572856000_73.5.1444.10
  doi: 10.1016/S0197-0186(02)00101-8
– ident: 2019081413572856000_73.5.1444.22
  doi: 10.1038/nrm1229
– ident: 2019081413572856000_73.5.1444.23
  doi: 10.1002/ana.20078
– ident: 2019081413572856000_73.5.1444.1
  doi: 10.1038/sj.jcbfm.9600445
– ident: 2019081413572856000_73.5.1444.17
  doi: 10.1073/pnas.98.3.1294
– ident: 2019081413572856000_73.5.1444.36
  doi: 10.1111/j.1528-1167.2006.00496.x
– ident: 2019081413572856000_73.5.1444.2
  doi: 10.1016/S0006-8993(99)01797-7
– ident: 2019081413572856000_73.5.1444.32
  doi: 10.1152/ajpheart.00520.2003
– ident: 2019081413572856000_73.5.1444.13
  doi: 10.1124/mol.104.001503
– ident: 2019081413572856000_73.5.1444.6
  doi: 10.1124/mol.106.023796
– ident: 2019081413572856000_73.5.1444.7
  doi: 10.1016/j.nbd.2006.06.014
– ident: 2019081413572856000_73.5.1444.31
  doi: 10.1358/mf.2003.25.2.723681
– ident: 2019081413572856000_73.5.1444.14
  doi: 10.1124/mol.105.017954
– ident: 2019081413572856000_73.5.1444.27
  doi: 10.1016/j.nbd.2007.04.002
– volume: 268
  start-page: F46
  year: 1995
  ident: 2019081413572856000_73.5.1444.30
  publication-title: Am J Physiol
– volume: 59
  start-page: S3
  issue: Suppl 5
  year: 2002
  ident: 2019081413572856000_73.5.1444.16
  publication-title: Neurology
– ident: 2019081413572856000_73.5.1444.33
  doi: 10.1089/089771502753754091
– ident: 2019081413572856000_73.5.1444.9
  doi: 10.1124/jpet.302.3.846
– ident: 2019081413572856000_73.5.1444.12
  doi: 10.1016/S0920-1211(01)00272-8
– ident: 2019081413572856000_73.5.1444.28
  doi: 10.1111/j.1471-4159.2005.03150.x
– ident: 2019081413572856000_73.5.1444.5
  doi: 10.1124/mol.106.029512
– ident: 2019081413572856000_73.5.1444.20
  doi: 10.1586/14737175.6.3.397
– ident: 2019081413572856000_73.5.1444.21
  doi: 10.1016/j.nbd.2006.08.015
– ident: 2019081413572856000_73.5.1444.3
  doi: 10.2174/0929867033456800
– ident: 2019081413572856000_73.5.1444.8
  doi: 10.1016/S0306-4522(03)00027-7
SSID ssj0014580
Score 2.435986
Snippet Increased expression of drug efflux transporters at the blood-brain barrier accompanies epileptic seizures and complicates therapy with antiepileptic drugs....
Increased expression of drug efflux transporters at the blood-brain barrier accompanies epileptic seizures and complicates therapy with antiepileptic drugs....
SourceID proquest
crossref
pubmed
highwire
SourceType Aggregation Database
Index Database
Publisher
StartPage 1444
SubjectTerms Animals
ATP-Binding Cassette, Sub-Family B, Member 1 - genetics
Blood-Brain Barrier - drug effects
Blood-Brain Barrier - enzymology
Blood-Brain Barrier - pathology
Capillaries - drug effects
Capillaries - enzymology
Capillaries - pathology
Cyclooxygenase 2 - metabolism
Female
Glutamic Acid - pharmacology
Hippocampus - drug effects
Hippocampus - enzymology
Indomethacin
Male
Mice
Mice, Inbred C57BL
Pilocarpine
Protein Biosynthesis - drug effects
Rats
Rats, Sprague-Dawley
Rats, Wistar
Receptors, N-Methyl-D-Aspartate - metabolism
Seizures - chemically induced
Seizures - pathology
Signal Transduction - drug effects
Transcription, Genetic - drug effects
Up-Regulation - genetics
Title Seizure-Induced Up-Regulation of P-Glycoprotein at the Blood-Brain Barrier through Glutamate and Cyclooxygenase-2 Signaling
URI http://molpharm.aspetjournals.org/content/73/5/1444.abstract
https://www.ncbi.nlm.nih.gov/pubmed/18094072
https://search.proquest.com/docview/20691803
Volume 73
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKeOEFcadsgB_QeOg8msRJ7Md12kVojIqlUt8sx3GmspJUXSvR8Qf42RzHTpMOEJeXKIpyU74v52L7fAehN0EacG2GwDJNFaHKzwhLwz6heW6EUFmUVeXRH86j0xF9Pw7Hnc731qql5SLdVze_rCv5H1ThGOBqqmT_Adn1TeEA7AO-sAWEYftXGF_oyc1yronpv2Hm8Ucz8sn2lndh4JCcTFeqrMQYJoUrXOwNqsXqA9Mcwsw3VD3r6n49J_C-EqJYO6twuFJw7tcVvAF4O-L3LiaXJnJ37q7uBFW32O3NGiHsplBCLi0tBp9LPS8akzevWsn2DorJlWyNjQ_1ldLKCRs0iwSSUk-nRbMEZO4kw-sRC9asD1xXEESE8XBsfZAzvL4Z1nCG11lm2-TEMTBsmVnIAmnLZXvUCg7_7A58Chh-Kaf7npGqpEYtrXF89WT_-UdxPDo7E8nROLmD7vpgsqLKxK8TKXgAs8VM7s2d_Cfc_93m3TfDm1py-vfpSxXGJA_QfZd_4ANLpoeoo4tHaHdocVvt4aSpx7vew7t42EL0Mfp2i3F4g3G4zPEm47BcYGAcbjEOO8Zhxzi8ZhwGxuHbjMNrxj1Bo-Oj5PCUuPYdRFHfWxDOaV8pT_YDySFxjrXKo5THkMNmTEsGcStnMpNK0VSHOmI51YEKfeOe4VKpgqdoqygL_RzhKI1CbjIDL_OoZAqyfJbFXkp5zkJf8S56W391MbMqLaLKbn0qAB_Yj4XFp4te16CI9j8h4kCEwvAKzqixEmBqzfyZLHS5vBZ-P-Ie6wdd9MxC2DyLGRnK2H_xx2u30b3ml9hBW4v5Ur-EsHaRvqoY9wPj_qZn
link.rule.ids 315,783,787,27936,27937
linkProvider ABC ChemistRy
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Seizure-Induced+Up-Regulation+of+P-Glycoprotein+at+the+Blood-Brain+Barrier+through+Glutamate+and+Cyclooxygenase-2+Signaling&rft.jtitle=Molecular+pharmacology&rft.au=Bauer%2C+Bjoern&rft.au=Hartz%2C+Anika+MS&rft.au=Pekcec%2C+Anton&rft.au=Toellner%2C+Kathrin&rft.date=2008-05-01&rft.issn=0026-895X&rft.eissn=1521-0111&rft.volume=73&rft.issue=5&rft.spage=1444&rft.epage=1453&rft_id=info:doi/10.1124%2Fmol.107.041210&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0026-895X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0026-895X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0026-895X&client=summon